The drug is dosed once every four weeks – compared with Mounjaro and Wegovy’s weekly dosing – but the company also signaled it is considering extended dosing intervals.
It’s still early days, but the first set of data on Amgen, Inc.’s bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist and glucagon-like peptide-1 (GLP-1) receptor agonist molecule, AMG 133, suggest it could gain an advantage on the market with its efficacy, durability and less frequent dosing in treating obesity than competing drugs.
Amgen presented data for AMG 133 on 3 December at the World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease...
The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.
After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.
Coartem Baby to be rolled out in eight African countries in the autumn.
Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.
KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.
The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.
Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.
